Here, we demonstrate that our nanobody-based CAR engineered EBVSTs provide a tumor-agnostic strategy to target diverse types of B7-H3–positive solid tumors while overcoming some of the hurdles that have impeded clinical advancement of CAR T cells against such tumors. The gene discussed is CD276; the disease is neoplasm.